Who
Alexandra Kropotova
Director
Company insider
Files Form 4 as: Director, iBio; Chief Medical Officer, SAB Biotherapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 14 Oct 2020
- Last trade
- 14 Oct 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 15 Oct 2026 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —473 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —473 | filing |
| 25 Jun 2026filed 26 Jun 2026 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —988 | filing |
| 25 Jun 2026filed 26 Jun 2026 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —988 | filing |
| 24 Mar 2026filed 25 Mar 2026 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —988 | filing |
| 24 Mar 2026filed 25 Mar 2026 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —988 | filing |
| 3 Feb 2026filed 5 Feb 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,400,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,400,000 at $0.00 | filing |
| 11 Dec 2025filed 12 Dec 2025 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —988 | filing |
| 20 Nov 2025filed 24 Nov 2025 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 19 Sep 2025filed 22 Sep 2025 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —1,977 | filing |
| 26 Aug 2025filed 28 Aug 2025 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,400,000 at $0.00 | filing |
| 27 Mar 2025filed 1 Apr 2025 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —1,179 | filing |
| 18 Dec 2024filed 31 Dec 2024 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code F | —9,072 | filing |
| 21 Nov 2024filed 25 Nov 2024 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,900 at $0.00 | filing |
| 21 Feb 2024filed 23 Feb 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 14 Mar 2023filed 16 Mar 2023 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —275,000 | filing |
| 13 Sep 2022filed 15 Sep 2022 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,325 at $0.00 | filing |
| 6 Jun 2022filed 7 Jun 2022 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.